A Phase I, open-label, non-randomized study to evaluate the absorption, distribution, metabolism and excretion and pharmacokinetics of DLX313 (minzasolmin) following a single oral dose of [14C]DLX313 in healthy male participants

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507959-29-00

Acronym

CDLX313A12101

Enrollment

Registered

2024-07-16

Start date

2024-07-19

Completion date

2024-09-14

Last updated

2024-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson’s Disease

None listed

Sex/Gender

Male

Age

18 Years to 64 Years

Netherlands

None listed

Source: EU CTIS · Data processed: Feb 4, 2026